Search Orphan Drug Designations and Approvals
-
Generic Name: | tetravalent tandem diabody binding both CD3 and CD33 |
---|---|
Date Designated: | 08/17/2017 |
Orphan Designation: | Treatment of patients with acute myeloid leukemia (AML) |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Amphivena Therapeutics, Inc. 601 Gateway Boulevard Suite 350 South San Francisco, California 94080 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-